CY1113409T1 - Αναστολεις ακτ και ρ70 s6 κινασης - Google Patents
Αναστολεις ακτ και ρ70 s6 κινασηςInfo
- Publication number
- CY1113409T1 CY1113409T1 CY20121100928T CY121100928T CY1113409T1 CY 1113409 T1 CY1113409 T1 CY 1113409T1 CY 20121100928 T CY20121100928 T CY 20121100928T CY 121100928 T CY121100928 T CY 121100928T CY 1113409 T1 CY1113409 T1 CY 1113409T1
- Authority
- CY
- Cyprus
- Prior art keywords
- acth
- formula
- suspension suspensions
- compounds
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει αναστολείς ΑΚΤ και p70 S6 κινάσης του Τύπου (I). Η παρούσα εφεύρεση παρέχει επίσης φαρμακευτικές συνθέσεις που περιέχουν ενώσεις του Τύπου (I), χρήσεις των ενώσεων του Τύπου (I) και μεθόδους χρήσεως των ενώσεων του Τύπου (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11327308P | 2008-11-11 | 2008-11-11 | |
EP09744896A EP2358710B1 (en) | 2008-11-11 | 2009-11-03 | Akt and p70 s6 kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1113409T1 true CY1113409T1 (el) | 2016-06-22 |
Family
ID=41402451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100928T CY1113409T1 (el) | 2008-11-11 | 2012-10-05 | Αναστολεις ακτ και ρ70 s6 κινασης |
Country Status (37)
Country | Link |
---|---|
US (1) | US8148387B2 (el) |
EP (1) | EP2358710B1 (el) |
JP (1) | JP5432275B2 (el) |
KR (1) | KR101334460B1 (el) |
CN (1) | CN102216302B (el) |
AR (1) | AR074072A1 (el) |
AU (1) | AU2009314324B2 (el) |
BR (1) | BRPI0921916A2 (el) |
CA (1) | CA2743019C (el) |
CO (1) | CO6382114A2 (el) |
CR (1) | CR20110240A (el) |
CY (1) | CY1113409T1 (el) |
DK (1) | DK2358710T3 (el) |
DO (1) | DOP2011000129A (el) |
EA (1) | EA018947B1 (el) |
EC (1) | ECSP11011048A (el) |
ES (1) | ES2391704T3 (el) |
HK (1) | HK1158203A1 (el) |
HN (1) | HN2011001247A (el) |
HR (1) | HRP20120738T1 (el) |
IL (1) | IL211940A (el) |
JO (1) | JO2822B1 (el) |
MA (1) | MA32776B1 (el) |
MX (1) | MX2011005000A (el) |
MY (1) | MY161461A (el) |
NZ (1) | NZ592062A (el) |
PA (1) | PA8846901A1 (el) |
PE (1) | PE20110807A1 (el) |
PL (1) | PL2358710T3 (el) |
PT (1) | PT2358710E (el) |
RS (1) | RS52520B (el) |
SI (1) | SI2358710T1 (el) |
TN (1) | TN2011000207A1 (el) |
TW (1) | TWI422587B (el) |
UA (1) | UA100190C2 (el) |
WO (1) | WO2010056563A1 (el) |
ZA (1) | ZA201102549B (el) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA33501B1 (fr) | 2009-07-02 | 2012-08-01 | Sanofi Sa | Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
BR112012011328A2 (pt) * | 2009-10-23 | 2016-11-22 | Lilly Co Eli | inibidores de akt |
MA35016B1 (fr) | 2011-04-07 | 2014-04-03 | Bayer Ip Gmbh | Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt |
WO2013007167A1 (zh) * | 2011-07-09 | 2013-01-17 | 山东轩竹医药科技有限公司 | 二肽基肽酶-iv抑制剂的盐的晶型i及其制备方法和应用 |
PT2755965T (pt) * | 2011-09-12 | 2017-11-02 | Merck Patent Gmbh | Novas imidazol aminas como moduladores da atividade quinase |
MX347241B (es) | 2011-09-12 | 2017-04-20 | Merck Patent Gmbh | Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa. |
ES2807539T3 (es) * | 2012-11-16 | 2021-02-23 | Merck Patent Gmbh | Derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa |
EP2920178B1 (en) | 2012-11-16 | 2016-12-21 | Merck Patent GmbH | Novel heterocyclic derivatives as modulators of kinase activity (p70s6 and akt) |
ES2746756T3 (es) * | 2013-03-11 | 2020-03-06 | Merck Patent Gmbh | Derivados de 6-[4-(1H-imidazol-2-il)piperidin-1-il]pirimidin-4-amina como moduladores de la actividad cinasa |
CN105980375A (zh) * | 2014-02-11 | 2016-09-28 | 默克专利有限公司 | 用作激酶活性调节剂的嘧啶咪唑胺 |
TW201718574A (zh) | 2015-08-12 | 2017-06-01 | 美國禮來大藥廠 | Cgrp受體拮抗劑 |
MX2018014022A (es) * | 2016-05-20 | 2019-04-04 | Taiho Pharmaceutical Co Ltd | Derivado de 5h-pirrolo[2,3-d]pirimidin-6(7h)-ona novedoso. |
KR20220154722A (ko) | 2020-03-17 | 2022-11-22 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 융합된 이환식 유도체, 이의 제조 방법, 및 이의 약학적 용도 |
CN113444110B (zh) * | 2020-03-25 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用 |
CN117940410A (zh) | 2021-09-17 | 2024-04-26 | 江苏恒瑞医药股份有限公司 | 一种稠合二环类衍生物的可药用盐、晶型及其制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005249380C1 (en) | 2004-04-23 | 2012-09-20 | Exelixis, Inc. | Kinase modulators and methods of use |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
EP1848719B1 (en) | 2004-12-28 | 2012-02-01 | Exelixis, Inc. | [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
US7423043B2 (en) * | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
EP1907383A1 (en) | 2005-06-30 | 2008-04-09 | Prosidion Limited | Gpcr agonists |
EP2043655A2 (en) | 2006-04-25 | 2009-04-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
EP2037931A2 (en) | 2006-04-25 | 2009-03-25 | Astex Therapeutics Limited | Pharmaceutical combinations of pk inhibitors and other active agents |
WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
AR064416A1 (es) * | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
-
2009
- 2009-10-28 AR ARP090104158A patent/AR074072A1/es unknown
- 2009-10-29 TW TW098136731A patent/TWI422587B/zh not_active IP Right Cessation
- 2009-10-29 PA PA20098846901A patent/PA8846901A1/es unknown
- 2009-10-29 JO JO2009400A patent/JO2822B1/en active
- 2009-11-03 BR BRPI0921916A patent/BRPI0921916A2/pt not_active IP Right Cessation
- 2009-11-03 KR KR1020117010569A patent/KR101334460B1/ko not_active IP Right Cessation
- 2009-11-03 DK DK09744896.3T patent/DK2358710T3/da active
- 2009-11-03 EP EP09744896A patent/EP2358710B1/en active Active
- 2009-11-03 EA EA201170680A patent/EA018947B1/ru not_active IP Right Cessation
- 2009-11-03 PT PT09744896T patent/PT2358710E/pt unknown
- 2009-11-03 NZ NZ592062A patent/NZ592062A/xx not_active IP Right Cessation
- 2009-11-03 ES ES09744896T patent/ES2391704T3/es active Active
- 2009-11-03 UA UAA201105367A patent/UA100190C2/ru unknown
- 2009-11-03 CA CA2743019A patent/CA2743019C/en not_active Expired - Fee Related
- 2009-11-03 JP JP2011536383A patent/JP5432275B2/ja active Active
- 2009-11-03 RS RS20120443A patent/RS52520B/en unknown
- 2009-11-03 MX MX2011005000A patent/MX2011005000A/es active IP Right Grant
- 2009-11-03 SI SI200930348T patent/SI2358710T1/sl unknown
- 2009-11-03 MY MYPI2011002030A patent/MY161461A/en unknown
- 2009-11-03 CN CN2009801449532A patent/CN102216302B/zh active Active
- 2009-11-03 PL PL09744896T patent/PL2358710T3/pl unknown
- 2009-11-03 AU AU2009314324A patent/AU2009314324B2/en not_active Ceased
- 2009-11-03 WO PCT/US2009/063020 patent/WO2010056563A1/en active Application Filing
- 2009-11-03 US US12/611,139 patent/US8148387B2/en active Active
- 2009-11-03 PE PE2011001018A patent/PE20110807A1/es not_active Application Discontinuation
-
2011
- 2011-03-24 IL IL211940A patent/IL211940A/en not_active IP Right Cessation
- 2011-04-06 ZA ZA2011/02549A patent/ZA201102549B/en unknown
- 2011-04-25 TN TN2011000207A patent/TN2011000207A1/fr unknown
- 2011-05-03 HN HN2011001247A patent/HN2011001247A/es unknown
- 2011-05-06 CR CR20110240A patent/CR20110240A/es unknown
- 2011-05-09 MA MA33822A patent/MA32776B1/fr unknown
- 2011-05-09 DO DO2011000129A patent/DOP2011000129A/es unknown
- 2011-05-11 EC EC2011011048A patent/ECSP11011048A/es unknown
- 2011-05-12 CO CO11058555A patent/CO6382114A2/es active IP Right Grant
- 2011-11-24 HK HK11112734.3A patent/HK1158203A1/xx not_active IP Right Cessation
-
2012
- 2012-09-17 HR HRP20120738AT patent/HRP20120738T1/hr unknown
- 2012-10-05 CY CY20121100928T patent/CY1113409T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1113409T1 (el) | Αναστολεις ακτ και ρ70 s6 κινασης | |
EA200971051A1 (ru) | Ингибиторы p70 s6 киназы | |
CY1113386T1 (el) | Αναστολεις πρωτεασωματος | |
PH12015501484A1 (en) | Heteroaryl compounds and uses thereof | |
CY1112828T1 (el) | Ενωσεις αναστολης της μιτωτικης διαδικασιας | |
EA200970156A1 (ru) | Пиридизиноновые производные | |
TW201713640A (en) | Bruton's tyrosine kinase inhibitors | |
CY1114539T1 (el) | Η χρησιμοτητα των ιμιδαζοπυριδαζινοκαρβονιτριλιων ως αναστολεων κινασων | |
BR112012008385A2 (pt) | inibidores de p13 cinase e uso dos mesmos. | |
ATE547415T1 (de) | Inhibitoren der wechselwirkung zwischen mdm2 und p53 | |
CR20110028A (es) | Derivados de pirimidina como inhibidores de cinasa | |
ATE527253T1 (de) | Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer | |
CY1111752T1 (el) | Πυρρολοπυραζολες, δυναμικοι αναστολεις κινασης | |
EA201270590A1 (ru) | Ингибиторы акт | |
UA112281C2 (uk) | Стабільні інсектицидні композиції і способи їх отримання | |
MY153915A (en) | Organic compounds | |
EA201000777A1 (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
EA200870217A1 (ru) | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции | |
DK2134691T3 (da) | Quinolinonderivativer som parp- og tank-inhibitorer | |
EA201170227A1 (ru) | Имидазолкарбоксамиды | |
CY1109010T1 (el) | γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ | |
ECSP099634A (es) | Derivados de piridazinona útiles como inhibidores de glucano sintasa | |
UA109775C2 (xx) | N-вмісні гетероарильні похідні як інгібітори jak3-кінази | |
EA201070395A1 (ru) | Ингибиторы polo-подобных киназ | |
EA201071224A1 (ru) | Ингибиторы limk2, композиции, содержащие их, и способы их применения |